In-Person Inspections Remain US FDA’s Preference Despite ‘Virtual’ Options
FDA continues to see in-person inspections as more efficient and more effective than ‘virtual’ alternatives, which means almost all domestic inspections will be handled by traditional site visits.
You may also be interested in...
Draft guidance outlines how the agency will use RIEs as COVID-19 becomes endemic and agency staff are generally able to travel for site inspections – and how manufacturing facilities should prepare for them.
House Republicans keep the pressure on the US FDA for plans to catch up on inspections after the long COVID-19 hiatus. Recent cancer drug shortages could be a headline event to lead into a larger probe.
Records reviews are common now in lieu of an in-person inspection for US generic applications, but more virtual facility checks could be coming soon.